Which is the most common mechanism of action among the currently available lipid-lowering drugs used in clinical practice?

Explanation

## Most Common Mechanism of Hypolipidemic Drugs ### Overview of Hypolipidemic Drug Classes and Mechanisms | Drug Class | Mechanism | Frequency of Use | LDL Reduction | Clinical Impact | |---|---|---|---|---| | **Statins** (HMG-CoA reductase inhibitors) | Inhibit rate-limiting enzyme in cholesterol synthesis | Most common (>80% of lipid-lowering prescriptions) | 20–55% | First-line; proven CV benefit | | Fibrates | Activate PPAR-α; increase lipoprotein lipase | Moderate use (~10%) | 5–20% | Mainly TG reduction | | Bile acid sequestrants | Bind bile acids in intestine; increase fecal loss | Rare (<2%) | 15–30% | Older agent; GI side effects | | Ezetimibe | Inhibit Niemann-Pick C1-like 1 protein; block cholesterol absorption | Moderate use (~15%) | 15–20% | Adjunctive to statins | | PCSK9 inhibitors | Prevent LDLR degradation; increase LDL clearance | Growing use (~5%) | 40–60% | Very expensive; for statin-intolerant | | CETP inhibitors | Block cholesterol ester transfer protein | Rare (<1%) | Variable | Limited clinical data; not widely adopted | ### Key Point **Key Point:** Statins (HMG-CoA reductase inhibitors) are the most commonly prescribed hypolipidemic agents worldwide, accounting for >80% of lipid-lowering drug prescriptions. They are the first-line therapy for both primary and secondary prevention of cardiovascular disease. ### High-Yield Facts **High-Yield:** - Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis - They reduce LDL-C by 20–55% depending on the agent and dose - Proven reduction in cardiovascular morbidity and mortality in multiple landmark trials (4S, WOSCOPS, AFCAPS/TexCAPS, HPS, ASCOT-LLA) - All other hypolipidemic classes are used as adjuncts or in specific scenarios (fibrates for hypertriglyceridemia, ezetimibe for additional LDL reduction, PCSK9 inhibitors for statin-intolerant patients) ### Clinical Pearl **Clinical Pearl:** Although newer agents like PCSK9 inhibitors and inclisiran offer greater LDL reduction, statins remain the cornerstone of lipid management because of their proven cardiovascular benefit, safety profile, and cost-effectiveness. The dominance of statins in clinical practice reflects their superior evidence base and accessibility. ### Why Statins Are Most Common 1. **Efficacy:** 20–55% LDL reduction; pleiotropic benefits (anti-inflammatory, endothelial function) 2. **Safety:** Well-tolerated; adverse effects manageable 3. **Evidence:** Decades of RCT data demonstrating CV benefit 4. **Cost:** Generic formulations widely available and affordable 5. **Guidelines:** First-line recommendation in all major guidelines (ACC/AHA, ESC, NICE) ### Comparison of Other Mechanisms - **Lipoprotein lipase activation (fibrates):** Used primarily for hypertriglyceridemia; not first-line for LDL reduction - **Bile acid sequestration:** Older mechanism; GI side effects limit use; rarely used as monotherapy - **CETP inhibition:** Experimental mechanism; limited clinical adoption due to lack of proven CV benefit [cite:KD Tripathi 8e Ch 31]